Cargando…
Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future
Innovations in infectious disease testing have improved our abilities to detect and understand the microbial world. The 2019 novel coronavirus infectious disease (COVID-19) pandemic introduced new innovations including non-prescription “over the counter” infectious disease tests, mass spectrometry-b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735816/ https://www.ncbi.nlm.nih.gov/pubmed/34998789 http://dx.doi.org/10.1016/j.clinbiochem.2021.12.011 |
_version_ | 1784628324931207168 |
---|---|
author | Tran, Nam K. Albahra, Samer Rashidi, Hooman May, Larissa |
author_facet | Tran, Nam K. Albahra, Samer Rashidi, Hooman May, Larissa |
author_sort | Tran, Nam K. |
collection | PubMed |
description | Innovations in infectious disease testing have improved our abilities to detect and understand the microbial world. The 2019 novel coronavirus infectious disease (COVID-19) pandemic introduced new innovations including non-prescription “over the counter” infectious disease tests, mass spectrometry-based detection of COVID-19 host response, and the implementation of artificial intelligence (AI) and machine learning (ML) to identify individuals infected by the severe acute respiratory syndrome - coronavirus – 2 (SARS-CoV-2). As the world recovers from the COVID-19 pandemic; these innovative solutions will give rise to a new era of infectious disease tests extending beyond the detection of SARS-CoV-2. To this end, the purpose of this review is to summarize current trends in infectious disease testing and discuss innovative applications specifically in the areas of POC testing, MS, molecular diagnostics, sample types, and AI/ML. |
format | Online Article Text |
id | pubmed-8735816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Canadian Society of Clinical Chemists. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87358162022-01-07 Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future Tran, Nam K. Albahra, Samer Rashidi, Hooman May, Larissa Clin Biochem Article Innovations in infectious disease testing have improved our abilities to detect and understand the microbial world. The 2019 novel coronavirus infectious disease (COVID-19) pandemic introduced new innovations including non-prescription “over the counter” infectious disease tests, mass spectrometry-based detection of COVID-19 host response, and the implementation of artificial intelligence (AI) and machine learning (ML) to identify individuals infected by the severe acute respiratory syndrome - coronavirus – 2 (SARS-CoV-2). As the world recovers from the COVID-19 pandemic; these innovative solutions will give rise to a new era of infectious disease tests extending beyond the detection of SARS-CoV-2. To this end, the purpose of this review is to summarize current trends in infectious disease testing and discuss innovative applications specifically in the areas of POC testing, MS, molecular diagnostics, sample types, and AI/ML. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. 2023-07 2022-01-05 /pmc/articles/PMC8735816/ /pubmed/34998789 http://dx.doi.org/10.1016/j.clinbiochem.2021.12.011 Text en © 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tran, Nam K. Albahra, Samer Rashidi, Hooman May, Larissa Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future |
title | Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future |
title_full | Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future |
title_fullStr | Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future |
title_full_unstemmed | Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future |
title_short | Innovations in infectious disease testing: Leveraging COVID-19 pandemic technologies for the future |
title_sort | innovations in infectious disease testing: leveraging covid-19 pandemic technologies for the future |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735816/ https://www.ncbi.nlm.nih.gov/pubmed/34998789 http://dx.doi.org/10.1016/j.clinbiochem.2021.12.011 |
work_keys_str_mv | AT trannamk innovationsininfectiousdiseasetestingleveragingcovid19pandemictechnologiesforthefuture AT albahrasamer innovationsininfectiousdiseasetestingleveragingcovid19pandemictechnologiesforthefuture AT rashidihooman innovationsininfectiousdiseasetestingleveragingcovid19pandemictechnologiesforthefuture AT maylarissa innovationsininfectiousdiseasetestingleveragingcovid19pandemictechnologiesforthefuture |